For this type of tumour, one study published in several scientific journals [42, 103, 104] investigated the safety and efficacy of long-term add-on mistletoe therapy (median of almost 4.5 years) following surgery. Patients receiving conventional chemo-/and or radiotherapy and patients receiving additional mistletoe therapy were compared.
It was found that in the mistletoe group, only one in five experienced side effects due to chemotherapy or radiotherapy, while in the comparison group without mistletoe therapy, every other patient suffered from side effects. In addition, patients in the mistletoe group developed fewer disease-related and therapy-related symptoms such as nausea, vomiting, loss of appetite, depression, fatigue, insomnia, irritability, mucositis or skin reactions.
Hospital stay in the mistletoe group was on average six days shorter than in the control group and they experienced less symptoms of fatigue.
In addition, tumour-free survival in the mistletoe group was significantly longer than in patients without mistletoe therapy.
Mistletoe therapy itself was well tolerated, with few mild to moderate side effects.
In the section "Scientific Information" we have presented the results of this study in detail.
Last update: May 1st, 2020/AB